Vyne Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $86 | $130 | $169 | $69 |
Gross Profit | 80 | 130 | 169 | 69 |
EBITDA | -3,579 | -4,951 | -7,420 | -5,741 |
EBIT | -3,585 | -4,956 | -7,426 | -5,747 |
Net Income | -3,585 | -4,837 | -7,280 | -5,755 |
Net Change In Cash | 86 | 130 | 169 | 69 |
Free Cash Flow | -4,081 | -3,764 | -7,096 | -10,803 |
Cash | 24,631 | 24,027 | 19,346 | 22,047 |
Basic Shares | 42,768 | 42,768 | 42,745 | 42,759 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $570 | $501 | $424 | $477 |
Gross Profit | 547 | 501 | 424 | 477 |
EBITDA | -26,732 | -39,799 | -27,872 | -33,860 |
EBIT | -39,803 | -29,003 | -33,932 | |
Net Income | -26,483 | -39,834 | -28,452 | -23,210 |
Net Change In Cash | 570 | 501 | 424 | 477 |
Free Cash Flow | -33,124 | -34,089 | -25,341 | -29,200 |
Cash | 24,027 | 19,926 | 30,620 | 30,908 |
Basic Shares | 42,768 | 42,589 | 10,273 | 3,185 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.08 |
2025-12-31 | -$0.11 |
2025-09-30 | -$0.17 |
2025-06-30 | -$0.13 |